rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LFCR
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Lifecore Biomedical earnings missed by $0.82, revenue fell short of estimates
      Nov 4Investing.comLFCR
      Lifecore Biomedical: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceLFCR
      Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
      Nov 4Yahoo FinanceLFCR
      Is Lifecore Biomedical (LFCR) an Asymmetric Risk-Reward in Pharma Contract Manufacturing?
      Oct 23Yahoo FinanceLFCR
      Lifecore Biomedical sets record date for special stockholder meeting on merger
      Oct 20Investing.comLFCR
      Lifecore Biomedical Q2 2026 Earnings Call Transcript - Lifecore Biomedical (NASDAQ:LFCR)

      Lifecore Biomedical (NASDAQ:LFCR) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data

      Oct 8BenzingaLFCR
      Lifecore Biomedical to Participate at Upcoming Industry Conferences
      Oct 7Yahoo FinanceLFCR
      Lifecore Biomedical (LFCR) was downgraded to a Hold Rating at William Blair

      Detailed price information for Lifecore Biomedical Inc (LFCR-Q) from The Globe and Mail including charting and trades.

      Oct 6The Globe and MailLFCR
      Lifecore Biomedical Extends Key Manufacturing Pact with Alcon

      Detailed price information for Lifecore Biomedical Inc (LFCR-Q) from The Globe and Mail including charting and trades.

      Sep 30The Globe and MailLFCR
      $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)
      Sep 29MorningstarLFCR
      Lifecore Biomedical: Bid Is Underwhelming (NASDAQ:LFCR)

      Lifecore Biomedical agreed to be acquired for $6.28/share in cash plus up to $3.39/share in CVRs. See why I rate LFCR stock a Hold right now.

      Sep 29Seeking AlphaLFCR
      Craig-Hallum Downgrades Lifecore Biomedical to Hold From Buy, Adjusts PT to $6.28 From $9

      Lifecore Biomedical (LFCR) has an average rating of hold and mean price target of $5.84, according t

      Sep 29Yahoo FinanceLFCR
      Lifecore Extends Manufacturing Contract With Alcon Research
      Sep 29Yahoo FinanceLFCRALC
      William Blair Downgrades Lifecore Biomedical to Market Perform From Outperform
      Sep 29Yahoo FinanceLFCR
      Barrington Downgrades Lifecore Biomedical to Market Perform From Outperform, Removes $6.25 Price Target
      Sep 29Yahoo FinanceLFCR
      LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC.
      Sep 28MorningstarLFCR
      Lifecore Biomedical to Be Acquired by Webster Equity Partners for Up to $663 Million

      Lifecore Biomedical (LFCR) said Monday it agreed to be acquired by Webster Equity Partners in a tran

      Sep 28Yahoo FinanceLFCR
      Webster Equity Partners to acquire Lifecore for up to $663.7m
      Sep 28Investing.comLFCR
      Lifecore Biomedical to be Acquired by Webster Equity Partners

      Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% PremiumLifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at ClosingBoth Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance MilestonesStockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CV

      Sep 28Yahoo FinanceLFCR
      Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business (NASDAQ:LFCR)
      Sep 14Seeking AlphaLFCR
      Lifecore Biomedical to Participate at CPHI Global Conference

      CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference. The conference will take place October 6-8, 2026, in Milan, Italy. Details regarding Lifecore’s participation are as follows: CPHI Global Conference Details: Lifecore leaders, including Mark DaFonseca, chief commercial of

      Sep 3Yahoo FinanceLFCR
      Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company

      -- Significant New Program Positioned to Become One of Lifecore’s Largest Contracts -- -- Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Drug Product -- -- Program Expected to Contribute to 2028 Commercial Revenues -- CHASKA, Minn., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed a new agreement t

      Sep 2Yahoo FinanceLFCR

      This is the newest page. Registered accounts read further back.